|
1
|
Wang L, Shi J and Zhang Y: Influences of
simvastatin on vascular endothelial function of patients with
coronary heart disease complicated with congestive heart failure.
Eur Rev Med Pharmacol Sci. 17:1590–1593. 2013.PubMed/NCBI
|
|
2
|
Hayashi H, Fukuma N, Kato K, Kato Y,
Takahashi H and Mizuno K: Clinical backgrounds and the time course
of sleep-disordered breathing in patients after myocardial
infarction. J Nippon Med Sch. 80:192–199. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Longhini C, Molino C and Fabbian F:
Cardiorenal syndrome: still not a defined entity. Clin Exp Nephrol.
14:12–21. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ronco C, Kaushik M, Valle R, Aspromonte N
and Peacock WF 4th: Diagnosis and management of fluid overload in
heart failure and cardio-renal syndrome: the ‘5B’ approach. Semin
Nephrol. 32:129–141. 2012.
|
|
5
|
Ronco C: Cardiorenal syndromes: definition
and classification. Contrib Nephrol. 164:33–38. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shchekochikhin D, Schrier RW and
Lindenfeld J: Cardiorenal syndrome: pathophysiology and treatment.
Curr Cardiol Rep. 15:3802013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Weir MR: Effects of renin-angiotensin
system inhibition on end-organ protection: can we do better? Clin
Ther. 29:1803–1824. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bader M and Ganten D: Update on tissue
renin-angiotensin systems. J Mol Med (Berl). 86:615–621. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Plumb RD, El-Sherbeeny NA, Dixon LJ, et
al: NAD(P)H-dependent superoxide production in platelets: the role
of angiotensin II and protein kinase C. Clin Biochem. 38:607–613.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Parlakpinar H, Ozer MK, Cicek E, Cigremis
Y, Vardi N and Acet A: Renal damage in rats induced by myocardial
ischemia/reperfusion: Role of nitric oxide. Int J Urol.
13:1327–1332. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Koike H, Sada T and Mizuno M: In vitro and
in vivo pharmacology of olmesartan medoxomil, an angiotensin II
type AT1 receptor antagonist. J Hypertens Suppl. 19:S3–S14. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Venugopal J, Rajeswari R, Shayanti M,
Sridhar R, Sundarrajan S, Balamurugan R and Ramakrishna S: Xylan
polysaccharides fabricated into nanofibrous substrate for
myocardial infarction. Mater Sci Eng C Mater Biol Appl.
33:1325–1331. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ronco C, McCullough P, Anker SD, et al;
Acute Dialysis Quality Initiative (ADQI) consensus group.
Cardio-renal syndromes: report from the consensus conference of the
acute dialysis quality initiative. Eur Heart J. 31:703–711. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shah BN and Greaves K: The cardiorenal
syndrome: a review. Int J Nephrol. 2011:9201952010.PubMed/NCBI
|
|
15
|
Coresh J, Astor BC, Greene T, Eknoyan G
and Levey AS: Prevalence of chronic kidney disease and decreased
kidney function in the adult US population: Third National Health
and Nutrition Examination Survey. Am J Kidney Dis. 41:1–12. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ritz E: Heart and kidney: fatal twins? Am
J Med. 119(5 Suppl 1): S31–S39. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Raizada V, Skipper B, Luo W and Griffith
J: Intracardiac and intrarenal renin-angiotensin systems:
mechanisms of cardiovascular and renal effects. J Investig Med.
55:341–359. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Souza ÁP, Sobrinho DB, Almeida JF, et al:
Angiotensin II type 1 receptor blockade restores
angiotensin-(1–7)-induced coronary vasodilation in hypertrophic rat
hearts. Clin Sci (Lond). 125:449–459. 2013.
|
|
19
|
Shao W, Seth DM, Prieto MC, Kobori H and
Navar LG: Activation of the renin-angiotensin system by a low-salt
diet does not augment intratubular angiotensinogen and angiotensin
II in rats. Am J Physiol Renal Physiol. 304:F505–F514. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nishiyama A: Mechanisms responsible for
the renoprotective effects of renin-angiotensin inhibitors.
Yakugaku Zasshi. 132:455–459. 2012.(In Japanese).
|
|
21
|
Kashihara N, Haruna Y, Kondeti VK and
Kanwar YS: Oxidative stress in diabetic nephropathy. Curr Med Chem.
17:4256–4269. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Panda SS1, Bajpai M, Sinha A, Mallick S
and Sharma MC: Effect of ipsilateral ureteric obstruction on
contralateral kidney and role of renin angiotensin system blockade
on renal recovery in experimentally induced unilateral ureteric
obstruction. J Indian Assoc Pediatr Surg. 18:58–61. 2013.
View Article : Google Scholar
|
|
23
|
Wolf G: Renal injury due to
renin-angiotensin-aldosterone system activation of the transforming
growth factor-beta pathway. Kidney Int. 70:1914–1919.
2006.PubMed/NCBI
|
|
24
|
Maki T, Nasa Y, Tanonaka K, Takahashi M
and Takeo S: Beneficial effects of sampatrilat, a novel
vasopeptidase inhibitor, on cardiac remodeling and function of rats
with chronic heart failure following left coronary artery ligation.
J Pharmacol Exp Ther. 305:97–105. 2003. View Article : Google Scholar
|
|
25
|
Wen ZZ, Cai MY, Mai Z, et al: Angiotensin
II receptor blocker attenuates intrarenal renin-angiotensin-system
and podocyte injury in rats with myocardial infarction. PLoS One.
8:e672422013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Volpe M, Savoia C, De Paolis P, et al: The
renin-angiotensin system as a risk factor and therapeutic target
for cardiovascular and renal disease. J Am Soc Nephrol. 13(Suppl
3): S173–S178. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Berk BC: Angiotensin type 2 receptor
(AT2R): a challenging twin. Sci STKE. 181:PE162003.PubMed/NCBI
|
